Review article · 2025 · Open access

Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment

Yamile Abuchard Anaya, Mariana Barragan, Ricardo Pequeno Bracho, Salique H. Shaham, Debasish Bandyopadhyay, Elias George, Diane Duyen Thuy Nguyen, Manish Kumar Tripathi

Cancer, 131(21), e70132 · Published 18 October 2025 · DOI 10.1002/cncr.70132

Open PDFView at the publisherCite this paper

In brief

“Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment” is a 2025 review article by Yamile Abuchard Anaya and 7 co-authors, published in Cancer. OpenAlex counts 28 citations as of 19 November 2026, which puts it in the top 5% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Cancer.

Citations
28
Most cited in
2026 (25)
Field-weighted impact
1.90
References
115
Authors
8

Abstract

Proteolysis-targeting chimeras (PROTACs) have the potential to revolutionize cancer treatment by specifically targeting and degrading oncogenic proteins. Using the ubiquitin-proteasome system, PROTACs allow the selective degradation of disease-causing proteins, including those traditionally deemed "undruggable" by conventional small-molecule inhibitors. By catalytically eliminating rather than inhibiting proteins, PROTACs provide sustained target suppression with lower doses and reduced toxicity. Their bifunctional design linking a protein of interest to an E3 ligase drives targeted ubiquitination and subsequent proteasomal degradation. Recent progress demonstrates promise in treating solid and hematologic malignancies, with several candidates advancing to clinical trials. This review provides a comprehensive overview of developing PROTACs, from understanding their mechanism to clinical applications, and highlights their emerging role in overcoming drug resistance and advancing the limits of cancer treatment. In addition, the authors discuss the challenges of optimizing PROTACs, including issues related to pharmacokinetics, E3 ligase compatibility, and the delivery of PROTACs to tumors. With their modularity, adaptability, and precision, PROTACs represent a next-generation platform for personalized cancer therapy across various patient groups.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Anaya, Y. A., Barragan, M., Bracho, R. P., Shaham, S. H., Bandyopadhyay, D., George, E., Nguyen, D. D. T., & Tripathi, M. K. (2025). Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment. Cancer, 131(21), e70132. https://doi.org/10.1002/cncr.70132

MLA 9

Anaya, Yamile Abuchard, et al. “Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment.” Cancer, vol. 131, no. 21, 2025, p. e70132. https://doi.org/10.1002/cncr.70132.

Chicago

Anaya, Yamile Abuchard, Mariana Barragan, Ricardo Pequeno Bracho, Salique H. Shaham, Debasish Bandyopadhyay, Elias George, Diane Duyen Thuy Nguyen, and Manish Kumar Tripathi. 2025. “Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment.” Cancer 131 (21): e70132. https://doi.org/10.1002/cncr.70132.

Harvard

Anaya, Y. A. et al. (2025) ‘Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment’, Cancer, 131(21), p. e70132. doi:10.1002/cncr.70132.

IEEE

Y. A. Anaya et al., “Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment,” Cancer, vol. 131, no. 21, p. e70132, 2025, doi: 10.1002/cncr.70132.

BibTeX

@article{anaya2025proteolysis,
  title     = {{Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment}},
  author    = {Anaya, Yamile Abuchard and Barragan, Mariana and Bracho, Ricardo Pequeno and Shaham, Salique H. and Bandyopadhyay, Debasish and George, Elias and Nguyen, Diane Duyen Thuy and Tripathi, Manish Kumar},
  journal   = {Cancer},
  year      = {2025},
  volume    = {131},
  number    = {21},
  pages     = {e70132},
  doi       = {10.1002/cncr.70132},
  url       = {https://doi.org/10.1002/cncr.70132}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • targeted protein degradation
  • ubiquitin-proteasome system
  • E3 ubiquitin ligase
  • undruggable targets
  • drug resistance
  • hematologic malignancies
  • solid tumors

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Anaya, Y. A., Barragan, M., Bracho, R. P., Shaham, S. H., Bandyopadhyay, D., George, E., Nguyen, D. D. T., & Tripathi, M. K. (2025). Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment. Cancer, 131(21), e70132. https://doi.org/10.1002/cncr.70132

How many times has this paper been cited?

28 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cancer: sign in and open the PDF from this page.

Who wrote this paper?

Yamile Abuchard Anaya, Mariana Barragan, Ricardo Pequeno Bracho, Salique H. Shaham, Debasish Bandyopadhyay, Elias George, Diane Duyen Thuy Nguyen, Manish Kumar Tripathi.

What is the DOI of this paper?

10.1002/cncr.70132, permanently at https://doi.org/10.1002/cncr.70132. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.